CD274 and ovarian carcinoma: In two Phase II trials of programmed cell death protein-1/ligand-1 (PD-1/PD-L1) inhibitors, pembrolizumab and avelumab showed little benefit in ovarian cancer cohorts[39-40]; however, it was hoped that in subgroups of patients including PNEOC patients, they may have a niche role.